Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

IMPORTANCE: Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundari...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Giugliano, Robert P., Keech, Anthony, Murphy, Sabina A., Huber, Kurt, Tokgozoglu, S. Lale, Lewis, Basil S., Ferreira, Jorge, Pineda, Armando Lira, Somaratne, Ransi, Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815002/
https://ncbi.nlm.nih.gov/pubmed/29117276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados